MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events - mediated through separate signaling processes and involving different target sites - in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-indepe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MCL-1 phosphorylation at T163 decreased acutely upon trametinib treatment consistent with a loss of ERK phosphorylation59 and then rebounded at later time points coinciding with activation of JNK (Fig. S11A).”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [59]
In the citing paper
“ERK1/2 stabilise MCL1 through phosphorylation of T163 and indirectly through RSK-mediated inhibition of GSK39.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [9]
In the citing paper
“ERK-mediated phosphorylation of the MCL-1-PEST domain has been reported to limit MCL-1 degradation.”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Domina et al., 2004
In the citing paper
“Our data therefore suggest that the induction of MCL-1 protein upon A-1155463 treatment could be mediated by FGFR4-driven ERK signaling (Domina et al., 2004) (Figure 5C).”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Domina et al., 2004
Citations
Cites
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393 · cited 2×
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundCurrent Protocols in Protein Science
(2018) · Current Protocols in Protein Science · doi:10.1002/(issn)1934-3663 · Cited by 1,189
Ca 2+ -Induced Apoptosis Through Calcineurin Dephosphorylation of BAD
Wang, H.-G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., & Reed, J. C. (1999) · Science · doi:10.1126/science.284.5412.339 · Cited by 1,132 · cited 2×
“This latter modification has been extensively characterized in the case of the proapoptotic family member BAD (Scheid et al., 1999; Wang et al., 1999; Harada et al., 2001).”
BackgroundTsujimoto, Y., & Croce, C. M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5214 · Cited by 1,106 · cited 1×
“Expression of such viability-regulating gene products is often aberrant in cancer, as exemplified by the BCL2 overexpression seen in follicular lymphoma (Tsujimoto and Croce, 1986).”
BackgroundYamamoto, K., Ichijo, H., & Korsmeyer, S. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8469 · Cited by 1,003 · cited 4×
“Conversion of Ser 70 and/or Ser 87 to Ala similarly resulted in enhanced viability promotion in human Jurkat or mouse WEHI231 cells (Yamamoto et al., 1999).”
BackgroundMethodInfluentialMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961 · cited 3×
“…and slows turnover of the MCL1 protein We focused first on further studies with TPA, since we have extensively examined the effects of this agent on MCL1 expression and phosphorylation (Kozopas et al., 1993; Yang et al., 1996; Zhou et al., 1997; Townsend et al., 1998, 1999; Domina et al., 2000).”
BackgroundSelf-citationGeneration of Destabilized Green Fluorescent Protein as a Transcription Reporter
Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C.-C., & Kain, S. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.34970 · Cited by 846 · cited 2×
“MCL1 turnover was assessed using standard methods (Li et al., 1998; Akgul et al., 2000; Gregory and Hann, 2000; Cuconati et al., 2003), by exposing cells to cycloheximide to inhibit protein synthesis (25 mg/ml) and monitoring loss of the existing MCL1 protein over time by Western blotting.”
MethodDevelopment and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801 · cited 1×
“A distinctive characteristic of MCL1 in these systems, as in differentiating cells like ML-1 cells, is its ability to act in a rapid but often shortterm fashion, under conditions of changing cell phenotype (Craig, 2002; Opferman et al., 2003).”
BackgroundPhosphorylation-Dependent Ubiquitination of Cyclin E by the SCF Fbw7 Ubiquitin Ligase
Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065203 · Cited by 762 · cited 1×
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundElimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591 · cited 1×
“Whatever the mechanism, the importance of MCL1 turnover in the control of cell viability has recently been brought to the fore by the demonstration that loss of MCL1 is an early step in apoptosis induced by DNA damage or by the viral E1A protein (Cuconati et al., 2003; Nijhawan et al., 2003).”
Background
Cited by
Items 101–200 of 342
Haarberg, H. E., Paraiso, K. H. T., Wood, E., Rebecca, V. W., Sondak, V. K., Koomen, J. M., & Smalley, K. S. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1003 · Cited by 55
“phorylation atT163,whichprevents its degradationby the proteasome (36, 41).”
BackgroundYe, M., Zhang, Y., Zhang, X., Zhang, J., Jing, P., Cao, L., Li, N., Li, X., Yao, L., Zhang, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3470 · Cited by 59
“CPD-2 is situated between codons 159 and 163 in the C-terminal region and contains GSK3b (34) and MEK/ERK (35) phosphorylation sites.”
BackgroundLocatelli, S. L., Cleris, L., Stirparo, G. G., Tartari, S., Saba, E., Pierdominici, M., Malorni, W., Carbone, A., Anichini, A., & Carlo‐Stella, C. (2014) · Leukemia · doi:10.1038/leu.2014.81 · Cited by 59
Dusp5 negatively regulates IL‐33‐mediated eosinophil survival and function
Holmes, D. A., Yeh, J.-H., Yan, D., Xu, M., & Chan, A. C. (2014) · The EMBO Journal · doi:10.15252/embj.201489456 · Cited by 62
“…can induce the transcription of Mcl1, Bcl2, and Bclxl mRNAs through direct binding of AP-1 and CREB to their promoter regions (Ballif & Blenis, 2001; Sevilla et al , 2001; McCubrey et al , 2007), as well as phosphorylate and stabilize MCL-1 and BCL-2 to promote cell survival (Domina et al , 2004).”
Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells
Li, B., Li, X., Ni, Z., Zhang, Y., Zeng, Y., Yan, X., Huang, Y., He, J., Lyu, X., Wu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10694 · Cited by 55
Kang, X.-H., Zhang, J.-H., Zhang, Q.-Q., Cui, Y.-H., Wang, Y., Kou, W.-Z., Miao, Z.-H., Lu, P., Wang, L.-F., Xu, Z.-Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475438 · Cited by 55
The Protein Kinase Cδ Catalytic Fragment Targets Mcl-1 for Degradation to Trigger Apoptosis
Sitailo, L. A., Tibudan, S. S., & Denning, M. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607351200 · Cited by 65
Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system
Chen, L. S., Balakrishnan, K., & Gandhi, V. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.039 · Cited by 55
“O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.”
BackgroundLiao, M., Zhao, J., Wang, T., Duan, J., Zhang, Y., & Deng, X. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-44 · Cited by 54
Li, X., Su, Y., Hege, K., Madlambayan, G., Edwards, H., Knight, T., Polin, L., Kushner, J., Dzinic, S. H., White, K., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.233445 · Cited by 51
Nifoussi, S. K., Vrana, J. A., Domina, A. M., Biasio, A. D., Gui, J., Gregory, M. A., Hann, S., & Craig, R. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047060 · Cited by 53
“1C, upper right), as in earlier studies [25].”
BackgroundMethodResultSelf-citationPétigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.-H., Abeilard, E., Denoyelle, C., Gauduchon, P., Poulain, L., & Villedieu, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0342 · Cited by 57
“Moreover, ERK contributes to Mcl-1 stability by phosphorylation (21).”
BackgroundSodium Salicylate Promotes Neutrophil Apoptosis by Stimulating Caspase-Dependent Turnover of Mcl-1
Derouet, M. F., Thomas, L. W., MOULDING, D. A., Akgul, C., Cross, A. L., Moots, R. J., & Edwards, S. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.957 · Cited by 53
“By this mechanism, sodium salicylate would prevent Erk-mediated phosphorylation of Thr163 on Mcl-1 and thus prevent GM-CSF from signaling increased stability (19).”
BackgroundInfluentialConcise Review: Leukemia Stem Cells in Personalized Medicine
Guzmán, M. L., & Allan, J. N. (2014) · Stem Cells · doi:10.1002/stem.1597 · Cited by 57
Beurlet, S., Omidvar, N., Gorombei, P., Krief, P., Pogam, C. L., Setterblad, N., de la Grange, P., Lebœuf, C., Janin, A., Noguera, M., et al. (2013) · Blood · doi:10.1182/blood-2012-07-445635 · Cited by 57
Singh, P. K., Roukounakis, A., Frank, D. O., Kirschnek, S., Das, K. K., Neumann, S., Madl, J., Römer, W., Zorzin, C., Borner, C., et al. (2017) · Genes & Development · doi:10.1101/gad.302497.117 · Cited by 52
“A role of Bim as a tumor suppressor has been confirmed in epithelial (Tan et al. 2005) and haematopoietic (Egle et al. 2004) cells, and Bim functions to determine the response of tumor cells to chemotherapy (Tan et al. 2005).”
Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
Carlisle, J. W., & Ramalingam, S. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0626 · Cited by 50
Sutherland, K. A., Rogers, H. L., Tosh, D., & Rogers, M. J. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2681 · Cited by 53
“In myeloid cells, Mcl-1 prevents apoptosis and its expression is highly regulated by survival-promoting factors via the PI3K/Akt/ mammlian target of rapamycin (mTOR)/S6 kinase as well as mitogen-activated protein kinase (MAPK) signalling pathways [39,40].”
BackgroundAzijli, K., Yuvaraj, S., van Roosmalen, I. A. M., Flach, K. D., Giovannetti, E., Peters, G. J., de Jong, S., & Kruyt, F. A. E. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0829-3 · Cited by 52
“Mcl-1 degradation was shown to be regulated through phosphorylation at different sites by ERK, JNK, and GSK-3b, and phosphorylation at Thr163 by ERK prolonged the Mcl-1 half-life [40].”
BackgroundYeh, Y.-Y., Chen, R., Hessler, J. D., Mahoney, E., Lehman, A. M., Heerema, N. A., Grever, M. R., Plunkett, W. K., Byrd, J. C., & Johnson, A. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2096 · Cited by 51
“[40] PEST sequence is enriched in proline, glutamic acid, serine, and threonine and is associated with proteins subjected to rapid degradation via the proteasome pathway.”
BackgroundRegulation of apoptosis by an intrinsically disordered region of Bcl-xL
Follis, A. V., Llambi, F., Kalkavan, H., Yao, Y., Phillips, A. H., Park, C.-G., Marassi, F. M., Green, D. R., & Kriwacki, R. W. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0011-x · Cited by 47
Hiraki, M., Suzuki, Y., Alam, M., Hinohara, K., Hasegawa, M., Jin, C., Kharbanda, S. M., & Kufe, D. W. (2016) · Scientific Reports · doi:10.1038/srep26643 · Cited by 50
Mao, S., Ling, Q., Pan, J., Li, F., Huang, S., Ye, W., Wei, W., Lin, X., Yu, Q., Wang, Y., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02848-9 · Cited by 47
Chong, S. J. F., Zhu, F., Dashevsky, O., Mizuno, R., Lai, J. X. H., Hackett, L. R., Ryan, C. E., Collins, M. C., Iorgulescu, J. B., Guièze, R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170169 · Cited by 47
“We specifically chose to assess the activity of kinases and kinase families (MAPKs, PKA/ C/D, CDKs, and AMPK) known to include at least 1 documented member that could affect the phosphorylation and stability of the BCL-2 family (7, 13–15 , 35– 40 ).”
Marini, K. D., Croucher, D. R., McCloy, R. A., Vaghjiani, V., González-Rajal, Á., Hastings, J. F., Chin, V. T., Szczepny, A., Kostyrko, K., Márquez, C. P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3504 · Cited by 45
Fecteau, J.-F., Bharati, I. S., O’Hayre, M., Handel, T. M., Kipps, T. J., & Messmer, D. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00164 · Cited by 44
“In addition, it was been shown that ERK activation can lead to Mcl-1 phosphorylation, which in turn increases its stability (39).”
BackgroundBoston, S. R., Deshmukh, R., Strome, S., Priyakumar, U. D., MacKerell, A. D., & Shapiro, P. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-7 · Cited by 43
“We also examined the test compounds effects on protein expression of Bad as well as Mcl-1, which is stabilized following ERK phosphorylation [38].”
BackgroundTRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1
Son, J.-Y., Varadarajan, S., & Bratton, S. B. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.9 · Cited by 46
Liu, J., Liu, D., Zhang, X., Li, Y., Fu, X., He, W., Li, M., Chen, P., Zeng, G., DiSanto, M. E., et al. (2021) · Clinical Science · doi:10.1042/cs20210476 · Cited by 44
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Al‐Odat, O. S., Suskil, M. V., Chitren, R. J., Elbezanti, W. O., Srivastava, S. K., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Aggarwal, B. B., & Pandey, M. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.699629 · Cited by 45
“Mcl-1 phosphorylation occurs by several protein kinases including; c-Jun N-terminal kinase (JNK) (Inoshita et al., 2002), glycogen synthase kinase 3 (GSK-3) (Maurer et al., 2006; Ding et al., 2007), and extracellular signal-regulated kinase (ERK-1) (Domina et al., 2004; Ding et al., 2008).”
BackgroundHuang, C., & Yang‐Yen, H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.07.013 · Cited by 49
“The best characterized post-transcriptional modification is phosphorylation, which is related to its protein stability [18,19].”
BackgroundCao, F., Gong, Y., Kang, X., Lu, Z., Wang, Y., Zhao, K., Miao, Z., Liao, M., & Xu, Z. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114662 · Cited by 42
Oncogenic BRAF signalling increases M cl‐1 expression in cutaneous metastatic melanoma
McKee, C. S., Hill, D. S., Redfern, C. P. F., Armstrong, J. L., & Lovat, P. E. (2013) · Experimental Dermatology · doi:10.1111/exd.12254 · Cited by 42
Matheson, E. C., Thomas, H. D., Case, M. C., Blair, H. J., Jackson, R. K., Mašić, D., Veal, G. J., Halsey, C., Newell, D. R., Vormoor, J. H., et al. (2019) · Haematologica · doi:10.3324/haematol.2017.185975 · Cited by 43
Zang, H., Qian, G., Arbiser, J. L., Owonikoko, T. K., Ramalingam, S. S., Fan, S., & Sun, S. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12645 · Cited by 43
“ERK phosphorylates Mcl-1 protein, resulting in its stabilization (Domina et al., 2004; Nifoussi et al., 2012).”
BackgroundBiasio, A. D., Vrana, J. A., Zhou, P., Qian, L., Bieszczad, C. K., Braley, K. E., Domina, A. M., Weintraub, S. J., Neveu, J. M., Lane, W. S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700938200 · Cited by 45
Self-citationMitochondrial Metabolism in Melanoma
Huang, C. Y., Radi, R., & Arbiser, J. L. (2021) · Cells · doi:10.3390/cells10113197 · Cited by 42
“Furthermore, MAPK1/3 activation also helps retain MCL1 expression by slowing the degradation of the protein via the phosphorylation of threonine 163 [117].”
BackgroundDarling, N. J., Balmanno, K., & Cook, S. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184907 · Cited by 42
Zhang, W., Ruvolo, V. R., Chen, G., Zhou, L., Bornmann, W. G., Tsao, T., Schober, W. D., Smith, P. D., Guichard, S. M., Konopleva, M. Y., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0576 · Cited by 38
“phosphorylation of Mcl-1 slows this turnover (37).”
Paiva, C. J., Rowland, T., Sreekantham, B., Godbersen, C., Best, S., Kaur, P., Loriaux, M., Spurgeon, S. E. F., Danilova, O. V., & Danilov, A. V. (2017) · Haematologica · doi:10.3324/haematol.2017.170571 · Cited by 38
Qiao, X., Ma, J., Knight, T. E., Su, Y., Edwards, H. J., Polin, L., Li, J., Kushner, J., Dzinic, S. H., White, K., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00502-7 · Cited by 38
Mcl-1 is vital for neutrophil survival
Murphy, M. P., & Caraher, E. M. (2015) · Immunologic Research · doi:10.1007/s12026-015-8655-z · Cited by 42
Pan, J., Quintás‐Cardama, A., Manshouri, T., Giles, F. J., Lamb, P., Tefferi, A., Cortes, J. E., Kantarjian, H. M., & Verstovšek, S. (2007) · Leukemia · doi:10.1038/sj.leu.2404714 · Cited by 41
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
Ramakrishnan, V. G., Miller, K. C., Macon, E. P., Kimlinger, T. K., Haug, J. L., Kumar, S., Gonsalves, W. I., Rajkumar, S. V., & Kumar, S. K. (2019) · Haematologica · doi:10.3324/haematol.2018.211110 · Cited by 37
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
Personeni, N., Rimassa, L., Pressiani, T., Destro, A., Ligorio, C., Tronconi, M. C., Bozzarelli, S., Carnaghi, C., Tommaso, L. D., Giordano, L., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1429-x · Cited by 37
SP-1 regulation of MMP-9 expression requires Ser586 in the PEST domain
Murthy, S., Ryan, A. J., & Carter, A. B. (2012) · Biochemical Journal · doi:10.1042/bj20120053 · Cited by 37
Cherla, R. P., Zhang, Y., Ledbetter, L., & Zhang, G. (2018) · Infection and Immunity · doi:10.1128/iai.00504-17 · Cited by 39
“Posttranslationally, Mcl-1 is phosphorylated at Thr-163 by Erk, which enhances its stability via prevention of degradation (63).”
BackgroundWhite, B. S., Khan, S. A., Mason, M. J., Ammad-ud-din, M., Potdar, S., Malani, D., Kuusanmäki, H. A., Druker, B. J., Heckman, C. A., Kallioniemi, O., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00209-9 · Cited by 40
MCL-1 is a clinically targetable vulnerability in breast cancer
Winder, M. L., & Campbell, K. J. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2054096 · Cited by 38
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
Vachhani, P. J., Bose, P., Rahmani, M., & Grant, S. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00173.2013 · Cited by 36
Nishioka, C., Ikezoe, T., Yang, J., & Yokoyama, A. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0372-4 · Cited by 35
Wang, B., Chen, L., Ni, Z., Dai, X., Qin, L., Wu, Y., Li, X., Xu, L., Lian, J., & He, F. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.039 · Cited by 34
Nicotine Enhances the Antiapoptotic Function of Mcl-1 through Phosphorylation
Zhao, J., Xin, M., Wang, T., Zhang, Y., & Deng, X. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0304 · Cited by 35
Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion
Young, A. I. J., Timpson, P., Gallego‐Ortega, D., Ormandy, C. J., & Oakes, S. R. (2017) · Cell Adhesion & Migration · doi:10.1080/19336918.2017.1393591 · Cited by 37
Hu, C.-J., Wang, B., Tang, B., Chen, B., Xiao, Y., Qin, Y., Yong, X., Luo, G., Zhang, J.-W., Zhang, D., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.008 · Cited by 33
Post, S. M., Ma, H., Malaney, P., Zhang, X., Aitken, M. J. L., Mak, P. Y., Ruvolo, V. R., Yasuhiro, T., Kozaki, R., Chan, L. E., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278369 · Cited by 34
Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Tantawy, S. I., Sarkar, A., Hubner, S., Tan, Z., Wierda, W. G., Eldeib, A., Zhang, S., Kornblau, S., & Gandhi, V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2088 · Cited by 34
Obesity Promotes Liver Carcinogenesis via Mcl-1 Stabilization Independent of IL-6Rα Signaling
Gruber, S., Straub, B. K., Ackermann, P. J., Wunderlich, C. M., Mauer, J., Seeger, J. M., Büning, H., Heukamp, L., Kashkar, H., Schirmacher, P., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.023 · Cited by 32
“In line with this notion, previous studies have suggested that MAPK/ ERK and JNK-dependent phosphorylation of Mcl-1 may also decrease Mcl-1 stability (Domina et al., 2004; Kodama et al., 2009; Morel et al., 2009).”
ResultBalakrishnan, K., Burger, J. A., Fu, M., Doifode, T., Wierda, W. G., & Gandhi, V. V. (2014) · Neoplasia · doi:10.1016/j.neo.2014.10.002 · Cited by 36
Yoon, H., Choi, Y., Song, J., Do, I., Kang, S. Y., Ko, Y. H., Song, S., & Kim, B.-G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088587 · Cited by 30
de Araujo, M. E. G., Erhart, G., Buck, K., Müller‐Holzner, E., Hubalek, M., Fiegl, H., Campa, D., Canzian, F., Eilber, U., Chang-Claude, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053768 · Cited by 30
“The ERK pathway regulates BcL-2, Bad, Mcl-1, Bim, Survivin and Caspase 9 [20,21,22].”
BackgroundSong, P., Yang, S., Hua, H. M., Zhang, H., Kong, Q., Wang, J., Luo, T. L., & Jiang, Y. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006029 · Cited by 29
“In addition, post-translational modifications of the PEST domains in MCL-1 regulate the stability of MCL-1 protein (15).”
BackgroundRuvolo, P. P., Ma, H., Ruvolo, V. R., Zhang, X., Mu, H., Schober, W. D., Hernandez, I., Gallardo, M., Khoury, J. D., Cortes, J. E., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.168856 · Cited by 31
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28
Fucoidan induces caspase-dependent apoptosis in MC3 human mucoepidermoid carcinoma cells
LEE, H.-E., Choi, E., Shin, J., Lee, S., Park, K., Cho, N., & Cho, S. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1368 · Cited by 28
“It has also been identified that ERK is an important regulator of Mcl‑1 stability (31).”
Bu, Q., Cui, L., Li, J., Du, X., Zou, W., Ding, K., & Pan, J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28931 · Cited by 28
“It has been reported that actived Erk1/2 stabilizes Mcl-1 through phosporylating its PEST region.(61) Sorafenib directly inhibited Erk1/2 to lower the expression of Mcl-1.”
BackgroundGrimberg-Peters, D., Büren, C., Windolf, J., Wahlers, T., & Paunel‐Görgülü, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161343 · Cited by 28
Katz, S. I., Zhou, L., Chao, G., Smith, C. D., Ferrara, T., Wang, W., Dicker, D. T., & El‐Deiry, W. S. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.24.10824 · Cited by 31
Abdel‐Aziz, A. K., Abdel‐Naim, A. B., Shouman, S. A., Minucci, S., & Elgendy, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00718 · Cited by 28
“…phosphorylation in its unique PEST region at Thr163 and Ser159 residues by extracellular signal regulated kinase (ERK) and glycogen synthase kinase 3β (GSK3β) respectively which in turn, diminishes and enhances the rate of Mcl-1 proteasomal degradation (Domina et al., 2004; Yan et al., 2017).”
BackgroundCDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax
Kour, S., Rana, S., Contreras, J. I., King, H. M., Robb, C. M., Sonawane, Y. A., Bendjennat, M., Crawford, A. J., Barger, C. J., Kizhake, S., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.116855 · Cited by 29
“There are several reported studies that provide mechanistic basis for the post-translational stabilization of Mcl-1 such as phosphorylation of key residues in the proline glutamic acid serine threonine domain of Mcl-1 (Domina et al., 2004).”
BackgroundPeris, I., Romero-Murillo, S., Martínez‐Balsalobre, E., Farrington, C. C., Arriazu, E., Marcotegui, N., Jiménez-Muñoz, M., Alburquerque-Prieto, C., Torres-López, A., Fresquet, V., et al. (2022) · Blood · doi:10.1182/blood.2022016466 · Cited by 28
Olianas, M. C., Dedoni, S., & Onali, P. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01530-2 · Cited by 27
“Among the latter, phosphorylation at Thr163 of the anti-apoptotic protein Mcl-1, a Bcl-2 family member which blocks the pro-apoptotic proteins Bak and Bax [48], has been shown to enhance Mcl-1 stability against proteasomal degradation [49].”
BackgroundKaufmann, S. H., Karp, J. E., Letendre, L., Kottke, T. J., Safgren, S. L., Greer, J., Gojo, I., Atherton, P. J., Svingen, P. A., Loegering, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0817 · Cited by 26
BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer
Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L., Nicotra, A., Stassi, G., & Medema, J. P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110374 · Cited by 26
“Our data therefore suggest that the induction of MCL-1 protein upon A1155463 treatment could be mediated by FGFR4-driven ERK signaling (Domina et al., 2004) (Figure 5C).”
BackgroundLin, L., Ding, D., Xiao, X., Li, B., Cao, P., & Li, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15336 · Cited by 25
Jenkins, L. J., Luk, I. Y., Fairlie, W. D., Lee, E. F., Palmieri, M., Schoffer, K. L., Tan, T., Ng, I., Vukelic, N., Tran, S. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0101 · Cited by 25
Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain
Demelash, A., Pfannenstiel, L. W., Tannenbaum, C. S., Li, X., Kalady, M. F., DeVecchio, J., & Gastman, B. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.663898 · Cited by 27
“of Mcl-1 are two major and two minor proline, glutamic acid, serine, and threonine (PEST) sequences that are targets of phosphorylation and contribute to the relatively short half-life of Mcl-1 (2–3 h) (28).”
BackgroundKawabata, T., Tanimura, S., Asai, K., Kawasaki, R., Matsumaru, Y., & Kohno, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319426 · Cited by 22
“PD0325901 induced dephosphorylation and subsequent accumulation of the pro-apoptotic protein BimEL (32) and elicited a slight down-regulation of the prosurvival protein Mcl-1 (17) in the cells (Fig.”
BackgroundThe Regulation of Platelet Life Span
Josefsson, E. C., Dowling, M. R., Lebois, M., & Kile, B. T. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00003-1 · Cited by 34
McCubrey, J. A., Sokolosky, M. L., Lehmann, B. D., Taylor, J. R., Navolanic, P. M., Chappell, W. H., Abrams, S. L., Stadelman, K. M., Wong, E. W. T., Misaghian, N., et al. (2008) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2008.02.006 · Cited by 32
Jin, Y., Ding, K., Li, H., Xue, M., Shi, X., Wang, C., & Pan, J. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-17 · Cited by 25
“Treatment for 24 h with ponatinib reduced the phosphorylation of Stat3, Stat5, Akt and Erk1/2 in cells expressing WT or T674I PDGFRα at 0.3-30 nM (Figure 1D) and over time (Figure 1E).”
BackgroundInfluentialCruz-Gordillo, P., Honeywell, M. E., Harper, N. W., Leete, T., & Lee, M. J. (2020) · Science Signaling · doi:10.1126/scisignal.abb9820 · Cited by 24
“Protein turnover is further regulated by phosphorylation of Mcl-1 by a variety of mitogen-activated protein kinases (MAPKs), which slows the protein turnover rate (51).”
BackgroundIkeda, D., Chi, S., Uchiyama, S., Nakamura, H., Guo, Y., Yamauchi, N., Yuda, J., & Minami, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115950 · Cited by 28
“MAPK and ERK, especially the pairs of MAPK1/ERK2 and MAPK3/ERK1, are involved in an essential component of MAP kinase signaling, regulating a variety of transcription factors (e.g., B-cell lymphoma 6 protein (BCL6) [62]), cytoskeletal elements, and regulators of apoptosis (e.g., myeloid cell leukemia 1 (MCL1) [63]).”
Stamelos, V. A., Redman, C. W. E., & Richardson, A. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-12 · Cited by 30
“Activation of the MAP-kinase (ERK) signalling cascade increases levels of MCL-1 through increased transcription [57] and increased protein stability [58].”
BackgroundSale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 20
“ERK1/2-mediated phosphorylation of Thr163 within this domain is proposed to stabilize MCL1 (Domina et al., 2004) whereas GSK3-catalysed phosphorylation within the PEST domain enhances MCL1 turnover (Maurer et al., 2006).”
BackgroundEPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation
Sun, H., Tsai, A.-C., Pan, S., Ding, Q., Yamaguchi, H., Lin, C.-N., Hung, M., & Teng, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0269 · Cited by 23
Zhao, W., Yu, D., Chen, Z., Yao, W., Yang, J., Ramalingam, S. S., & Sun, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.007 · Cited by 22
Green, S. E., Łuczak, M. W., Morse, J. L., DeLoughery, Z. J., & Zhitkovich, A. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft214 · Cited by 22
“Levels of MCL1 are particularly susceptible to regulatory changes, including via its stability controlled by the aminoterminal PEST domain (Domina et al., 2004).”
BackgroundModulation of Cell Death in Age-Related Diseases
Tezil, T., & Başağa, H. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660702 · Cited by 22
Anticancer therapy: boosting the bang of Bim
Hendrickson, A. W., Meng, X. W., & Kaufmann, S. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37553 · Cited by 23
Nifoussi, S. K., Ratcliffe, N. R., Ornstein, D. L., Kasof, G. M., Strack, S., & Craig, R. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.587873 · Cited by 22
“Although TPA activates ERK, which phosphorylates Thr163 (26, 27), OA appeared to maintain the basal ERK-independent Thr-163 phosphorylation that occurs in BL41-3 cells.”
InfluentialSelf-citationDeng, X. (2014) · Scientifica · doi:10.1155/2014/215426 · Cited by 21
“mediated phosphorylation at the Thr163 site enhances the half-life and antiapoptotic function of Mcl-1 [54, 55].”
BackgroundLee, Y., Chen, Y., Huang, C., & Chang, L. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1307-5 · Cited by 21
Du, W., Zhou, J., Wang, D., Gong, K., & Zhang, Q. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-60 · Cited by 21
“It has also been reported that ERK-mediated phosphorylation is an important regulator of Mcl-1 stability, and downregulation of Mcl-1 is one of the main antitumor effect of sorafenib, either alone or in combination with other agents, on several kinds of tumor cells [25,26].”
BackgroundEmerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis
Zhuang, J., & Brady, H. J. M. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401952 · Cited by 26
The role of post-translational modifications in the regulation of MCL1
Li, S., Guo, W., & Wu, H. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.109933 · Cited by 29
TAK1–JNK Axis Mediates Survival Signal through Mcl1 Stabilization in Activated T Cells
Hirata, Y., Sugie, A., Matsuda, A., Matsuda, S., & Koyasu, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202809 · Cited by 21
“Given the pivotal role of Mcl1 in protecting activated T cells from apoptosis (29–32) and that MAPK is able to phosphorylate and stabilize Mcl1 (33, 34), we reasoned that treatment with LLZ1640-2 result in the impaired expression of Mcl1 via inactivation of TAK1-JNK axis.”
BackgroundDolgikh, N., Hugle, M., Vogler, M., & Fulda, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1737 · Cited by 23
3-Chloroplumbagin Induces Cell Death in Breast Cancer Cells Through MAPK-Mediated Mcl-1 Inhibition
Kawiak, A., Domachowska, A., Królicka, A., Smolarska, M., & Łojkowska, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00784 · Cited by 19
“ERK has also been shown to increase cell survival through enhancing the stability and antiapoptotic activity of Mcl-1 through phosphorylation of Mcl-1 at Thr163 (Domina et al., 2004).”
BackgroundTan, Y., Li, T., Hu, M., Wang, B., Zhou, Q., Jiang, Y., Zhang, S., Duan, X., Yang, J., Liu, X., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110281 · Cited by 19
Metadata
- Authors
- Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W.
- Affiliations
- Dartmouth College (US)
- Vanderbilt University (US)
- Corresponding author
- Craig, Ruth W
- Venue
- Oncogene
- Published
- 2004-06-07
- Volume
- 23
- Issue
- 31
- Pages
- 5301-5315
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2041230280
- Cited by
- 327
- References
- 58
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 6 · 2023: 15 · 2022: 13 · 2021: 24 · 2020: 10 · 2019: 16 · 2018: 9 · 2017: 15 · 2016: 14 · 2015: 16 · 2014: 29 · 2013: 26 · 2012: 25
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hitchcock Foundation
- National Cancer Institute (R01-CA57359, R01CA057359)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Mcl-1, protein phosphorylation, ERK signaling, protein stabilization, Bcl-2 family proteins, anti-apoptotic proteins, okadaic acid, paclitaxel, microtubule stabilization, protein phosphatase 2A, phorbol myristate acetate, post-translational regulation, apoptosis
- MeSH terms
- Amino Acid Sequence, Animals, Antineoplastic Agents, Phytogenic, Binding Sites, Carcinogens, Cell Survival, Dogs, Dose-Response Relationship, Drug, Enzyme Activation, Enzyme Inhibitors, Cricetinae, Humans, Molecular Sequence Data, Neoplasm Proteins, Peptide Mapping, Phosphorylation, Precipitin Tests, Protein Kinase C, Tetradecanoylphorbol Acetate, Threonine, Time Factors, Transfection, Signal Transduction, CHO Cells, Apoptosis, Paclitaxel, Protein Structure, Tertiary, Proto-Oncogene Proteins c-bcl-2, Okadaic Acid, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.